BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 304376)

  • 1. Pharmacokinetics of high-dose methotrexate with citrovorum factor rescue.
    Isacoff WH; Morrison PF; Aroesty J; Willis KL; Block JB; Lincoln TL
    Cancer Treat Rep; 1977 Dec; 61(9):1665-74. PubMed ID: 304376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Essential laboratory determinations for monitoring high-dose methotrexate treatment with citrovorum factor rescue.
    Jürgens H; Ebell W; Bachmann R; Kupke I; Richter O; Andräs A; Göbel U
    Pediatr Pharmacol (New York); 1983; 3(3-4):157-65. PubMed ID: 6610851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose methotrexate: pharmacokinetics in children and young adults.
    Raude E; Oellerich M; Weinel P; Freund M; Schrappe M; Riehm H; Poliwoda H
    Int J Clin Pharmacol Ther Toxicol; 1988 Jul; 26(7):364-70. PubMed ID: 3209285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Age-related pharmacokinetics of high-dose methotrexate in patients with osteosarcoma.
    Wang YM; Sutow WW; Romsdahl MM; Perez C
    Cancer Treat Rep; 1979 Mar; 63(3):405-10. PubMed ID: 284845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of methotrexate and 7-hydroxymethotrexate following infusions of high-dose methotrexate.
    Breithaupt H; Küenzlen E
    Cancer Treat Rep; 1982 Sep; 66(9):1733-41. PubMed ID: 6956440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II clinical trial with high-dose methotrexate therapy and citrovorum factor rescue.
    Isacoff WH; Eilber F; Tabbarah H; Klein P; Dollinger M; Lemkin S; Sheehy P; Cone L; Rosenbloom B; Sieger L; Block JB
    Cancer Treat Rep; 1978 Sep; 62(9):1295-304. PubMed ID: 356984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significance of the 48-hour plasma level in high-dose methotrexate regimens.
    Perez C; Wang YM; Sutow WW; Herson J
    Cancer Clin Trials; 1978; 1(2):107-11. PubMed ID: 316368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methotrexate megadosage followed by folate rescue. I. A study in clearance patterns.
    Salasoo S; Irving MG; Lam-Po0Tang R; O'Gorman-Hughes D; Freedman A
    Med J Aust; 1976 May; 1(21):777-9. PubMed ID: 1085404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity.
    Stoller RG; Hande KR; Jacobs SA; Rosenberg SA; Chabner BA
    N Engl J Med; 1977 Sep; 297(12):630-4. PubMed ID: 302412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose methotrexate therapy of childhood acute lymphoblastic leukemia: lack of relation between serum methotrexate concentration and creatinine clearance.
    Joannon P; Oviedo I; Campbell M; Tordecilla J
    Pediatr Blood Cancer; 2004 Jul; 43(1):17-22. PubMed ID: 15170885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Therapy of solid tumors using high-dose methotrexate and citrovorum factor].
    Baumgartner G; Heinz R; Karrer K; Pridun N; Lutz D
    Osterr Z Onkol; 1977; 3(5-6):141-8. PubMed ID: 300863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The influence of liver and renal functions on the changes in serum methotrexate (MTX) level in high-dose MTX therapy].
    Sato T; Nakanishi K; Takahashi M; Sato K; Miura T; Kuzuya T; Mizuno M
    Gan To Kagaku Ryoho; 1990 Dec; 17(12):2375-9. PubMed ID: 2260874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Moderate dose methotrexate with citrovorum factor rescue therapy in the treatment of head and neck cancer].
    Inuyama Y; Hiroto I; Taketa C; Horiuchi M; Mashino S; Fujii M; Matsuura S; Satake B; Takeoda S; Nishijima W; Okuda M; Sakaguchi K; Tanigaito Y; Imakirei M; Konno T; Hirokawa T; Takada K; Ono I; Saitoh H; Takemiya S; Shimada F; Omura K; Miyake H; Fujii K; Kawabe Y; Kondoh T; Komiyama S; Yanagida T; Matsumura Y; Hirano M; Araki S
    Gan To Kagaku Ryoho; 1982 Dec; 9(12):2193-200. PubMed ID: 6764099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [l-folinic acid versus racemic folinic acid in the treatment of leukemia in children with high dose of methotrexate].
    Etienne MC; Thyss A; Bertrand Y; Rubie H; Milano G
    Bull Cancer; 1993 Apr; 80(4):357-63. PubMed ID: 8173189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methotrexate: bioavailability and pharmacokinetics.
    Campbell MA; Perrier DG; Dorr RT; Alberts DS; Finley PR
    Cancer Treat Rep; 1985; 69(7-8):833-8. PubMed ID: 3893694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of low-dose methotrexate in adult asthmatics.
    Glynn-Barnhart AM; Erzurum SC; Leff JA; Martin RJ; Cochran JE; Cott GR; Szefler SJ
    Pharmacotherapy; 1992; 12(5):383-90. PubMed ID: 1437699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antineoplastic agents: high-dose methotrexate and citrovorum factor rescue.
    Sadée W
    Ther Drug Monit; 1980; 2(2):177-85. PubMed ID: 6762711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delayed methotrexate clearance in osteosarcoma patients treated with multiagent regimens of neoadjuvant chemotherapy.
    Bacci G; Ferrari S; Longhi A; Forni C; Loro L; Beghelli C; Tremosini M; Versari M
    Oncol Rep; 2003; 10(4):851-7. PubMed ID: 12792734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effects of hydration on plasma concentrations of methotrexate in patients with osteosarcoma treated with high doses of methotrexate].
    Ferrari S; Orlandi M; Avella M; Caldora P; Ferraro A; Ravazzolo G; Bacci G
    Minerva Med; 1992 May; 83(5):289-93. PubMed ID: 1589134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Studies on high-dose methotrexate with citrovorum factor rescue therapy in children: analysis of bone marrow cell kinetics by flow cytometry].
    Tsurusawa M; Sasaki K; Matsuoka H; Katano N; Fujimoto T
    Gan To Kagaku Ryoho; 1985 Sep; 12(9):1827-32. PubMed ID: 3876075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.